HMGB1 and metabolic dysfunction-associated steatotic liver disease: In addition, circulating HMGB1 level also correlates with the severity of inflammation and hepatic fibrosis associated with NAFLD (Alisi et al. 2014; Ganz et al. 2015), and inhibition of HMGB1 release from hepatocytes, or treatment with neutralizing antibodies to HMGB1, attenuates liver damage during NAFLD (Zeng et al. 2015).